Radiopharm Theranostics reports 90% success rate in brain imaging trial

March 24, 2026 7:00 AM

Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced that 90% of patients in its Phase 2b clinical trial of RAD 101 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found